张吉翔
消化
副教授，副主任医师，硕士生导师
副教授，副主任医师，硕士生导师
导师介绍
| 姓名 | 张吉翔 |
| 出生年月 | 1986年7月 |
| 单位 | 武汉大学人民医院消化内科 |
| 所属学科 | 临床医学-内科学 |
| 职务、职称及头衔 | 副教授，副主任医师，硕士生导师 |
| zhangjixiang@whu.edu.cn | |
| 联系方式 | 13659857350 |
| 研究方向 |
1.炎症性肠病的基础与临床研究 2.消化道肿瘤的基础与临床研究 |
| 个人简介 | |
| 主要从事消化道肿瘤与炎症性肠病的基础和临床研究及医学教育研究，湖北名医工作室骨干成员，主持国家自然科学基金2项及其他省部级科研项目3项，以第一作者或通讯作者（包括共同第一或共同通讯）身份发表SCI论文20篇，其中ESI高被引论文2篇，副主编及参编参译教材及专著近10部，其中国家“十四五”规划教材1部。获湖北省高等学校教学成果奖一等奖1项、湖北省科技进步奖二等奖1项及武汉市科技进步奖三等奖1项。 | |
| 学术任职与荣誉 | |
| 中华医学会消化病学分会IBD学组心理协作组秘书 湖北省医学会消化病学工作秘书 吴阶平基金会中国炎症性肠病联盟青年委员 | |
| 教育履历 | |
|
2006.09-2011.06青海大学医学院临床医学专业本科生获学士学位 2011.09-2013.06武汉大学第一临床学院内科学硕士研究生获硕士学位 2013.09-2017.06武汉大学第一临床学院内科学博士研究生获博士学位 2015.10–2017.4,美国Texas A&M University,生物医学,联合培养博士 |
|
| 工作履历 | |
|
2021.12-至今 武汉大学人民医院副教授 2020.12-至今 武汉大学人民医院,消化内科,副主任医师 2017.12-2020.11 武汉大学人民医院,消化内科,主治医师 2017.7-2017.11 武汉大学人民医院,消化内科,医师 |
|
| 成果获奖 | |
|
1.湖北省高等学校教学成果奖一等奖1项 2.湖北省科技进步奖二等奖1项 3.武汉市科技进步奖三等奖1项 |
|
| 代表性论著 | |
|
[1] Wu X, Wei S, Chen M, Li J, Wei Y, Zhang J,
Dong W. P2RY13 Exacerbates Intestinal Inflammation by Damaging the Intestinal
Mucosal Barrier via Activating IL-6/STAT3 Pathway. Int J Biol Sci. 2022 Aug
1;18(13):5056-5069. (IF=10.750，二区，共同通讯作者) [2] Liu C, Yu R, Zhang J, Wei S, Xue F, Guo Y, He P, Shang L, Dong W. Research hotspot and trend analysis in the diagnosis of inflammatory bowel disease: A machine learning bibliometric analysis from 2012 to 2021. Front Immunol. 2022 Sep 14;13:972079. (IF=8.786，二区TOP期刊，共同第一作者) [3] Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, Wei J, Gong Z, Zhou C, Yu H, Yu M, Lei H, Cheng F, Zhang B, Xu Y, Wang G, Dong W. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020 Jun;26(6):767-772. (IF=13.310，一区，ESI高被引论文，被引351次，2020年中国消化领域高价值百篇SCI论文第八名) [4] Zhang J, Lei H, Hu X, Dong W. Hesperetin ameliorates DSS-induced colitis by maintaining the epithelial barrier via blocking RIPK3/MLKL necroptosis signaling. Eur J Pharmacol. 2020 Feb 6;873:172992. (IF=5.195，二区) [5] Zhang J, Tan P, Guo L, Gong J, Ma J, Li J, Lee M, Fang S, Jing J, Johnson G, Sun D, Cao WM, Dashwood R, Han L, Zhou Y, Dong WG, Huang Y. p53-dependent autophagic degradation of TET2 modulates cancer therapeutic resistance. Oncogene. 2019 Mar;38(11):1905-1919. (IF=8.756，一区) |
| Name | JIXIANG ZHANG |
| Date of birth | July，1986 |
| Department | Gastroenterology Department，Renmin Hospital,Wuhan University. |
| Title | Associate Professor, Master tutor |
| zhangjixiang@whu.edu.cn | |
| TEL | 13659857350 |
| Research Direction | |
|
1. Basic and clinical research of Inflammatory
bowel disease 2. Basic and Clinical Research on Gastrointestinal Tumors |
|
| Personal Profile | |
| He is mainly engaged in the basic and clinical research of digestive tract tumors and Inflammatory bowel disease. He is a key member of Hubei Famous Doctors Studio, presided over 2 scientific research projects of the National Natural Science Foundation of China and 3 other provinces and ministries, and published 20 SCI papers as the first author or correspondence author. The deputy editor in chief and co editor participated in nearly 10 translated textbooks and monographs, including 1 national "14th Five Year Plan" textbook. Received one first prize of the Hubei Provincial Higher Education Teaching Achievement Award, one second prize of the Hubei Provincial Science and Technology Progress Award, and one third prize of the Wuhan Science and Technology Progress Award. | |
| Selected Publications | |
|
[1] Wu X, Wei S, Chen M, Li J, Wei Y, Zhang J,
Dong W. P2RY13 Exacerbates Intestinal Inflammation by Damaging the Intestinal
Mucosal Barrier via Activating IL-6/STAT3 Pathway. Int J Biol Sci. 2022 Aug
1;18(13):5056-5069. [2] Liu C, Yu R, Zhang J, Wei S, Xue F, Guo Y, He P, Shang L, Dong W. Research hotspot and trend analysis in the diagnosis of inflammatory bowel disease: A machine learning bibliometric analysis from 2012 to 2021. Front Immunol. 2022 Sep 14;13:972079. [3] Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, Wei J, Gong Z, Zhou C, Yu H, Yu M, Lei H, Cheng F, Zhang B, Xu Y, Wang G, Dong W. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020 Jun;26(6):767-772. [4] Zhang J, Lei H, Hu X, Dong W. Hesperetin ameliorates DSS-induced colitis by maintaining the epithelial barrier via blocking RIPK3/MLKL necroptosis signaling. Eur J Pharmacol. 2020 Feb 6;873:172992. [5] Zhang J, Tan P, Guo L, Gong J, Ma J, Li J, Lee M, Fang S, Jing J, Johnson G, Sun D, Cao WM, Dashwood R, Han L, Zhou Y, Dong WG, Huang Y. p53-dependent autophagic degradation of TET2 modulates cancer therapeutic resistance. Oncogene. 2019 Mar;38(11):1905-1919. |
武汉大学人民医院
湖北省人民医院